 RedHill Biopharma Ltd. has reported important new data showing treatment with oral opaganib ABC294640 versus the placebo-controlled arm resulted in a 62 statistically significant reduction in mortality as well as statistically significant improved outcomes in time to room air and median time to hospital discharge in a group of 251 hospitalized, moderately severe coronavirus COVID-19 patients. 